Our Vision | Innovative Drug Development2019-02-02T15:23:42+00:00

Our Vision at Alzheon

We strive to bring transformational therapies to patients.

Passion
We are passionately dedicated to developing effective treatments for Alzheimer’s disease and other devastating neurodegenerative disorders.

Innovation
We are applying innovation to drug development in neurodegeneration by capitalizing on scientific and clinical insights, so we can rapidly and efficiently  move towards new therapeutic solutions with substantially lower development risk.

Patients
We are committed to improving the lives of patients, their families and caregivers.

Impact
We aim to develop breakthrough therapies that can change the lives of patients with neurodegenerative disorders.

Our Approach

Our Precision Medicine Approach in Alzheimer’s

Right Patients:  APOE4/4 early to mild Alzheimer’s

  • Homogeneous population overexpressing amyloid pathology
  • Focus on early to mild Alzheimer’s where amyloid oligomers play key role in disease progression 


Right Drug:
 
Improved ALZ-801 oral prodrug formulation

  • Consistent plasma levels provide for high brain penetration for oligomer inhibition
  • Improved oral absorption & GI tolerability
  • No vasogenic brain edema in tramiprosate clinical trials 


Right Trial: 
Phase 3 trial to confirm clinical efficacy in APOE4/4 patients

  • Phase 3 program authorized by FDA with validated cognitive & functional measures
  • Well tolerated, long-term safety evaluated in 2,000 patients at effective clinical dose
  • FDA agreed to use tramiprosate safety data for ALZ-801 NDA submission
  • Fast Track designation granted for ALZ-801 Alzheimer’s program

For Patients and Caregivers

We are not yet enrolling patients in our Phase 3 clinical trial with ALZ-801.

Please check back as we will update our website when we are ready to start our clinical trial.

5.7M People Suffer from Alzheimer’s in U.S. Alone1

35 Million Alzheimer’s Patients Worldwide2

Alzheon-Alzheimers-unmet-need

Alzheimer’s Disease is the 6th Leading Cause of Death

The Only Top Ten Cause of Death that Can’t be Prevented, Cured or Slowed

A growing problem in the U.S. due to aging population 

  • Disease characterized by
    1. Destructive memory loss, impaired ability to communicate & comprehend
    2. Inability to complete simple, familiar tasks, confusion with time & place
    3. Poor judgment & decision-making, becoming suspicious, depressed or anxious
    4. Death within 8-10 years from emergence of clinical symptoms
  • Currently 5.7 million people suffer from Alzheimer’s dementia
    • Number of patients will increase by ~70% over the next 12 years
  • 47 million with initial changes in the brain but not yet symptomatic
  • Direct healthcare costs = $277 billion (mostly Medicare)
  • Family & caregiver burden:  16 million people provide unpaid care at cost of $232 billion


In the U.S., by 2050 there will be

  • ~14 million people suffering from Alzheimer’s dementia
  • Healthcare & societal costs projected to balloon to $1.1 trillion
Alzheimer’s Association 2018; Brookmeyer 2017; World Alzheimer’s Reports 2018 & 2016